| abstract |
Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions. |